Article

5,000+ corneal inlays implanted

Given the global launch of a corneal inlay (Kamra) for the treatment of presbyopia and an investment by medical technology company Medtronic, AcuFocus says it has experienced significant procedural growth since 2010.

Irvine, CA-Given the global launch of a corneal inlay (Kamra) for the treatment of presbyopia and an investment by medical technology company Medtronic, AcuFocus says it has experienced significant procedural growth since 2010.

“This has been a tremendous year for growth in all areas of our business,” said Ed Peterson, AcuFocus president and chief executive officer.

AcuFocus is selling the intracorneal inlay in Europe, the Middle East, South America, and the Asia-Pacific region. More than 5,000 inlays have been implanted globally.

The company has invested more than 10 years of research and development into the device, with more than 1,000 patients participating in its worldwide clinical trials. The inlay received CE mark approval for use in the European Union in 2005. In the United States, it is considered to be an investigational device under an investigational device exemption.

The intracorneal inlay is designed to create a small aperture effect, allowing the eye to see near and intermediate objects more clearly. By applying the depth-of-focus principle commonly used in photography, the inlay allows only central rays to reach the retina through its fixed 1.6-mm opening.

The inlay is placed under a LASIK-type flap. A proprietary system (AcuTarget, AcuFocus) guides surgeons on proper surgical placement.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
I. Paul Singh, MD, speaks about glaucoma treatment and successful ophthalmic / optometric comanagement at the 19th Annual Controversies in Modern Eye Care meeting
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
© 2025 MJH Life Sciences

All rights reserved.